Coronary Artery DiseaseMaraCatNCT03738631
Cardiac Biomarkers After Marathon Running and Coronary Atherosclerosis
An observational study of Coronary Artery Disease, run by University of Turku at 1 site in Finland.
Trial summary
This study evaluates cardiac biomarkers and their association to coronary artery disease in marathon runners. Read more about this study
- Who is it for?
- Ages 35 to 90 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Coronary Artery Disease
- How many people
- 43 participants
- Where
- 1 siteFinland
- Study dates
- 17 Aug 2018to 1 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 90 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Male participants of the Paavo Nurmi Marathon 2018
Who may be able to join
- Age under 35 years or over 44 years
- Participant of Paavo Nurmi Marathon 2018
- Informed consent signed
Who cannot join
- No informed consent
- existing coronary artery disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Association of Cardiac Biomarker Elevation After Marathon Running and Coronary Atherosclerosis - the MaraCat Study
This study evaluates cardiac biomarkers and their association to coronary artery disease in marathon runners.
Read the detailed description
The MaraCat study is an observational prospective study evaluating the association between cardiac biomarkers and coronary artery disease in 43 runners participating in the 2018 Paavo Nurmi Marathon. The study participants were recruited according to two age criteria - under 35 years and over 44 years of age. Comprehensive laboratory samples were collected immediately after the run, while the control workup was done in a separate visit with no significant physical excercise in the preceding two weeks. In the under 35 years -group, the control workup included an echocardiography, ecg and blood samples. In the over 44 years group, the control studies included coronary CT, echocardiography, ecg and laboratory tests.
- Conditions
- Coronary Artery Disease
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Under 35 years | Not described | |
| Over 44 years | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiac Troponin-T level after marathon
Cardiac troponin-T levels (ng/L), [electrochemiluminescence (ECLIA) method]
Measured: 0-30minutes after finishing the Paavo Nurmi Marathon
Association Cardiac troponin-T level and coronary CT findings
Cardiac troponin-T levels (ng/L), [electrochemiluminescence (ECLIA) method]
Measured: Cardiac Troponin-T 0-30 minutes after finishing the Paavo Nurmi Marathon. Control Troponin-T levels and coronary CT angiography at control visit (>30days after marathon).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2018
- Study start17 Aug 2018
- Primary completion1 Dec 2022
- Study completion1 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Turku
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Juhani Airaksinen, Turku University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03738631
- Sponsor's protocol ID
- T171/2018
- Acronym
- MaraCat
- Status last verified
- May 2024
- First submitted
- 21 Sep 2018
- Last updated
- 8 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Cardiac Biomarker Elevation After Marathon Running and Coronary Atherosclerosis - the MaraCat Study
- ClinicalTrials.gov ID
- NCT03738631
- Acronym / sponsor ID
- MaraCat / T171/2018
- Conditions
- Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- University of TurkuUniversity, hospital or other
- Study start
- 17 Aug 2018 (actual)
- Primary completion
- 1 Dec 2022 (actual)
- Study completion
- 1 Dec 2022 (actual)
- First posted
- 13 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates cardiac biomarkers and their association to coronary artery disease in marathon runners.
Detailed description
The MaraCat study is an observational prospective study evaluating the association between cardiac biomarkers and coronary artery disease in 43 runners participating in the 2018 Paavo Nurmi Marathon. The study participants were recruited according to two age criteria - under 35 years and over 44 years of age. Comprehensive laboratory samples were collected immediately after the run, while the control workup was done in a separate visit with no significant physical excercise in the preceding two weeks. In the under 35 years -group, the control workup included an echocardiography, ecg and blood samples. In the over 44 years group, the control studies included coronary CT, echocardiography, ecg and laboratory tests.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Under 35 years | – | – |
| Over 44 years | – | – |
Who may qualify
- Ages
- 35 to 90 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Male participants of the Paavo Nurmi Marathon 2018
Key inclusion criteria (3 listed)
- Age under 35 years or over 44 years
- Participant of Paavo Nurmi Marathon 2018
- Informed consent signed
Key exclusion criteria (2 listed)
- No informed consent
- existing coronary artery disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cardiac Troponin-T level after marathon
Time frame: 0-30minutes after finishing the Paavo Nurmi Marathon
Cardiac troponin-T levels (ng/L), [electrochemiluminescence (ECLIA) method]
Association Cardiac troponin-T level and coronary CT findings
Time frame: Cardiac Troponin-T 0-30 minutes after finishing the Paavo Nurmi Marathon. Control Troponin-T levels and coronary CT angiography at control visit (>30days after marathon).
Cardiac troponin-T levels (ng/L), [electrochemiluminescence (ECLIA) method]
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by University of Turku at 1 site in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiac Troponin-T level after marathon (time frame: 0-30minutes after finishing the Paavo Nurmi Marathon). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2024.